View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
Catalent|13 July 2017

RP Scherer Softgel Technologies

An innovative biotechnology company exploring novel therapeutics for neuroscience indications had developed a promising new chemical entity for the treatment of a severe paediatric genetic disease.

Biotechnology company exploring novel therapeutics for neuroscience indications

An innovative biotechnology company exploring novel therapeutics for neuroscience indications had developed a promising new chemical entity for the treatment of a severe paediatric genetic disease.

However, numerous drug delivery challenges threatened the realisation of the fast-track status designation they had received due to promising early stage results.

By partnering with Catalent and leveraging our proprietary RP Scherer Softgel technology, the customer was able to overcome a number of potential hurdles and expeditiuosly enter the Phase II/III clinical trial.

Catalent utilised two technologies targeting duodenal and sublingual biological barriers through a parallel screening approach to assess the oral delivery potential of Salmon Calcitonin.
Catalent Pharma provided London-based pharmaceutical company Trio Medicines with three formulation technologies and four prototypes showing improved solubility and bioavailability for an acetyl prodrug of...
With Catalent's team of packaging experts and extensive cold chain capabilities, this case study discusses the creation of a custom packaging and distribution solution to...
The number of clinical trials in the Asia-Pacific (APAC) region is growing as sponsors tap into expanding pharmaceutical market.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology